SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Recruiting · NCT07474103 · Registry updated 2026-03-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2026-03-16 | NCT07474103 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 319 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hongli Liu | Wuhan | China | 1 |